Debregeas et Associés Pharma

Debregeas et Associés Pharma (D&A Pharma) is an independent French pharmaceutical company founded in 2006, specializing in the development and manufacturing of innovative medicines for high-unmet-need areas. The company focuses primarily on addiction medicine, including alcohol and opioid use disorders, as well as emergency care and gastroenterology. D&A Pharma operates an integrated model that combines internal R&D with industrial manufacturing capabilities across multiple sites in France, such as Laboratoires d'Houdan. Their lead commercial product, Alcover, is a sodium oxybate formulation used for the treatment of alcohol dependence and maintenance of abstinence. The group also provides contract development and manufacturing services (CDMO), leveraging expertise in complex oral dosage forms like pellets and microgranules.